Reducing Drug Craving Memories

NCT01319214 | Unknown

• 1 other identifier: 10-039-PSY
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary objective is to investigate the potential ability of Inderal (propranolol hydrochloride) to diminish the reconsolidation of motivationally potent drug-related cues in cocaine dependent participants. If effective in this laboratory model, Inderal may have clinical efficacy.

Conditions

Cocaine Addiction

Keywords

cocaine addiction treatment craving

Outcome Measures

Primary Outcomes (1)

• Self-report drug craving

  One day and one month after the intervention, the investigators will measure drug craving using visual analog scales (VAS) and the Cocaine Craving Questionnaire (CCQ).

  One day and one month post-treatment

Secondary Outcomes (1)

• Drug use

  One month after the intervention

Study Arms (4)

Inderal, neutral cues

EXPERIMENTAL

Drug: Inderal

Inderal, drug cues

EXPERIMENTAL

Drug: Inderal

Placebo, neutral cues

EXPERIMENTAL

Drug: Inderal

Placebo, drug cues

EXPERIMENTAL

Drug: Inderal

Interventions

Inderal DRUG

Inderal vs. placebo will be administered with or without cocaine cues

Inderal, drug cues; Inderal, neutral cues; Placebo, drug cues; Placebo, neutral cues

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• psychotropic medication-free men or women (15 subjects x 4 groups) who have met DSM-IV-TR diagnostic criteria for cocaine dependence for the past 6 months (age 18 - 50 years old);
• Minimum of three days cocaine abstinent on study days;
• Primary use of cocaine is intra-nasal or smoked crack

You may not qualify if:

• Medical conditions that might be aggravated by participation in the study:
• cardiovascular disorders that might be aggravated by participation in the study: hypotension (SBP: \< 100 mmHg), bradycardia (heart rate \< 60 /min), severe atrioventricular block (Type II or III), severe hypertension (SBP: \> 160 mmHg; DBP: \> 100 mmHg), myocardial infarction, history of chest pain and admission to ED for chest pain;
• respiratory disorders: bronchial asthma and chronic obstructive pulmonary disease;
• diabetic patients treated with insulin or oral hypoglycemic agents. Propranolol may mask the first signs of a developing hypoglycemia.
• Seropositive pregnancy test
• Comorbidity with current axis I psychiatric disorders other than anxiety, affective and substance use disorders
• Severe liver disfunction
• Current or recent (\< 5 half lives) use of medications that may interact with Inderal (see above)
• Positive urine tox screen for barbiturates. Positive breath alcohol screen. {Note: all urine tox screen results will be destroyed immediately after collection. The information will not be stored}

Sponsors & Collaborators

• McGill University Health Centre/Research Institute of the McGill University Health Centre: lead

MeSH Terms

Conditions

Cocaine-Related Disorders

Interventions

Propranolol

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Phenoxypropanolamines; Propanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Propanols; Amines; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: March 18, 2011
• First Posted: March 21, 2011
• Study Start: March 1, 2011
• Primary Completion: March 1, 2015
• Study Completion: March 1, 2015
• Last Updated: May 19, 2011

Record last verified: 2011-01